Amgen (AMGN) vs. Eli Lilly (LLY): Weighing Steady Growth Against High-Momentum Expansion
Key Takeaways
- AMGN and LLY both operate in the biopharmaceutical sector but differ markedly in scale and growth trajectories, with LLY demonstrating significantly higher recent revenue expansion driven by its GLP-1 portfolio.
- Recent market activity shows AMGN delivering steady single-digit revenue growth and maintaining consistent dividend payouts, while LLY reported 56% year-over-year revenue increase in the first quarter of 2026 alongside upward guidance revisions.
- Stock performance metrics indicate AMGN has achieved year-to-date returns of approximately 19% and one-year returns near 34%, compared to LLY's elevated valuation reflecting stronger momentum in obesity and diabetes treatments.
- Both companies face upcoming quarterly earnings releases in early August 2026, which could influence short-term sentiment amid broader sector positioning.
- Risk factors include regulatory developments for AMGN products and high valuation multiples for LLY, creating distinct trade-offs for investors seeking stability versus growth exposure.
Introduction
This comparison examines AMGN and LLY to highlight relative performance, business drivers, and market positioning in the current environment. Both companies represent established players in the biopharmaceutical industry, appealing to investors focused on healthcare innovation, dividend income, or high-growth opportunities within the sector. The analysis draws on verifiable financial metrics and recent developments to assist traders and portfolio managers in evaluating these stocks side by side. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
AMGN Overview and Recent Performance
Amgen Inc. develops and commercializes innovative therapies targeting serious illnesses in areas such as oncology, inflammation, and cardiovascular disease. In recent weeks, the stock has exhibited measured appreciation supported by product sales growth and operational execution. First-quarter 2026 revenues rose 6% year-over-year to $8.6 billion, with full-year guidance set at $37.1 billion to $38.5 billion. Recent market activity included a relief rally following updates on the Tavneos product and positioning ahead of second-quarter results. Year-to-date returns reached approximately 19%, with one-year performance near 34%. A quarterly dividend of $2.52 per share was declared for the third quarter of 2026, payable in September.
LLY Overview and Recent Performance
Eli Lilly and Company focuses on treatments for diabetes, obesity, oncology, and neuroscience, with particular strength in its glucagon-like peptide-1 (GLP-1) receptor agonist franchise. The company delivered robust first-quarter 2026 results, posting 56% revenue growth to $19.8 billion and raising full-year guidance to a range of $82 billion to $85 billion. In recent market activity, shares have traded near record levels around $1,149 amid sustained demand for its key medicines. Second-quarter earnings are scheduled for release on August 5, 2026. One-year returns have exceeded broader market benchmarks, reflecting the company's elevated growth profile, though the stock carries a premium valuation with a trailing price-to-earnings ratio above 40. From what I see, the momentum here stands out clearly.
Head-to-Head Comparison
AMGN operates with a diversified portfolio emphasizing established and emerging therapies, providing relative stability through consistent revenue streams and dividend distributions. In contrast, LLY benefits from concentrated exposure to high-demand GLP-1 therapies, driving outsized growth but introducing greater sensitivity to clinical and competitive developments. Recent momentum favors LLY on volume expansion, while AMGN shows steadier single-digit gains and lower beta characteristics. Sector exposure remains healthcare for both, yet LLY carries higher valuation multiples reflective of its growth trajectory. Market sentiment has been supportive of LLY's expansion narrative, whereas AMGN has seen incremental positive shifts from product-specific updates. Trade-offs center on growth potential versus income and defensive qualities.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue acceleration, and relative market positioning, Tickeron’s AI would currently assign a higher probability of favorable near-term performance to LLY due to its demonstrated growth catalysts and momentum indicators. AMGN offers complementary attributes in stability and income that could suit different risk profiles. This assessment reflects data-driven pattern recognition rather than forward-looking guarantees. I’m watching this closely as earnings approach.
Using AI Tools in My Research
In my analysis workflow, I frequently rely on Tickeron’s AI Trading Bots to test various scenarios across different market conditions. The platform features hundreds of bots executing strategies on thousands of tickers, with the Trending AI Robots section highlighting the top 25 performers from 351 options based on recent results. These tools help me explore automated approaches that align with specific objectives and volatility levels. For additional details, visit Trending AI Robots.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
AMGN's RSI Oscillator leaves overbought zone
The 10-day RSI Indicator for AMGN moved out of overbought territory on August 27, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 instances where the indicator moved out of the overbought zone. In of the 45 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMGN as a result. In of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMGN broke above its upper Bollinger Band on August 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 259 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.243) is normal, around the industry mean (19.270). P/E Ratio (27.157) is within average values for comparable stocks, (32.920). Projected Growth (PEG Ratio) (2.106) is also within normal values, averaging (10.088). Dividend Yield (0.023) settles around the average of (0.028) among similar stocks. P/S Ratio (6.238) is also within normal values, averaging (4.195).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement